Home
Pharmaceuticals
Brain Related Drug Development
Technology & Pipeline
Lantibiotics
Vaccine Program
Science & Technology
News & Media
Press Releases
In The News
Careers
Presentations
Publications
Abstracts
Investors
Investor Relations
Overview
News / Events
Press Releases
Email Alerts
IR Calendar
Company Info
Profile
Presentations
Management Team
Contacts
FAQ
Financial Info
Financials
Financial Results
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
About
Overview
Management Team
Board of Directors
Scientific Advisors
Contact Us
Careers
Home
Investors
News / Events
Press Releases
Investors
Overview
News / Events
Press Releases
Email Alerts
IR Calendar
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Email Alerts
Tear Sheet
Contacts
RSS News Feed
Press Releases
All News
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
February 5, 2024
Oragenics Announces Termination of At-The-Market Offering Program
January 23, 2024
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
January 2, 2024
« Previous
1
2
3
4
